Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES). (Q46818286)

From Wikidata

Jump to navigation Jump to search

scientific article published in September 2005

Language	Label	Description	Also known as
English	Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).	scientific article published in September 2005

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16306030

Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES). (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16306030

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Lowe SH

1

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16306030

Wensing AM

2

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16306030

Hassink EA

3

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16306030

ten Kate RW

4

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16306030

Richter C

5

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16306030

Schreij G

6

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16306030

Koopmans PP

7

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16306030

Juttmann JR

8

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16306030

van der Tweel I

9

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16306030

Lange JM

10

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16306030

Borleffs JC

11

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16306030

publication date

1 September 2005

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16306030

HIV Clinical Trials

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16306030

6

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16306030

5

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16306030

235-245

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16306030

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005).

1 reference

https://api.crossref.org/works/10.1310%2FA686-M37Y-J2PT-E9GJ

21 January 2018

Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy.

1 reference

https://api.crossref.org/works/10.1310%2FA686-M37Y-J2PT-E9GJ

21 January 2018

Starting highly active antiretroviral therapy: why, when and response to HAART.

1 reference

https://api.crossref.org/works/10.1310%2FA686-M37Y-J2PT-E9GJ

21 January 2018

Once‐a‐Day Highly Active Antiretroviral Therapy: A Systematic Review

1 reference

https://api.crossref.org/works/10.1310%2FA686-M37Y-J2PT-E9GJ

21 January 2018

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

1 reference

https://api.crossref.org/works/10.1310%2FA686-M37Y-J2PT-E9GJ

21 January 2018

Antiviral activity of enteric-coated didanosine, stavudine, and nelfinavir versus zidovudine plus lamivudine and nelfinavir

1 reference

https://api.crossref.org/works/10.1310%2FA686-M37Y-J2PT-E9GJ

21 January 2018

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects

1 reference

https://api.crossref.org/works/10.1310%2FA686-M37Y-J2PT-E9GJ

21 January 2018

Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results

1 reference

https://api.crossref.org/works/10.1310%2FA686-M37Y-J2PT-E9GJ

21 January 2018

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

1 reference

https://api.crossref.org/works/10.1310%2FA686-M37Y-J2PT-E9GJ

21 January 2018

A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1310%2FA686-M37Y-J2PT-E9GJ

21 January 2018

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

1 reference

https://api.crossref.org/works/10.1310%2FA686-M37Y-J2PT-E9GJ

21 January 2018

Saquinavir: a review of its use in boosted regimens for treating HIV infection

1 reference

https://api.crossref.org/works/10.1310%2FA686-M37Y-J2PT-E9GJ

21 January 2018

Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily

1 reference

https://api.crossref.org/works/10.1310%2FA686-M37Y-J2PT-E9GJ

21 January 2018

Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the Scan Study

1 reference

https://api.crossref.org/works/10.1310%2FA686-M37Y-J2PT-E9GJ

21 January 2018

Identifiers

10.1310/A686-M37Y-J2PT-E9GJ

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16306030

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16306030

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46818286&oldid=1577758069"